Incyte drops planned Phase 3 MAESTRA-3 study

Available on EDGAR 11/13/2026 - 04:09 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:09 PM EST

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Incyte Corporation decided not to proceed with the planned Phase 3 MAESTRA-3 study of INCB123667, its selective CDK2 inhibitor, combined with bevacizumab as first-line maintenance therapy for patients with ovarian cancer. The study had been expected to begin in the fourth quarter of 2026.

The company said the decision followed prioritization of its clinical development portfolio and was not based on safety or efficacy findings from the INCB123667 clinical program. Incyte does not expect the decision to affect its financial guidance or previously disclosed long-term outlook.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

None.

Negative

Moderate point. Forward-looking: it has not happened yet and may not happen.MAESTRA-3: planned Phase 3 study will not proceed.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Clinical study phase: Phase 3 Expected study start: Fourth quarter of 2026

2 metrics

Clinical study phase Phase 3 Planned MAESTRA-3 study

Expected study start Fourth quarter of 2026 MAESTRA-3 had been expected to begin then

Key Terms

selective CDK2 inhibitor, first-line maintenance therapy

2 terms

selective CDK2 inhibitor medical

"INCB123667, the Company’s selective CDK2 inhibitor"

first-line maintenance therapy medical

"as first-line maintenance therapy in patients with ovarian cancer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did INCY decide not to proceed with MAESTRA-3?

Incyte said it prioritized its clinical development portfolio; the decision was not based on safety or efficacy findings from the INCB123667 clinical program.

What was the INCY MAESTRA-3 study designed to evaluate?

MAESTRA-3 was designed to evaluate INCB123667, a selective CDK2 inhibitor, with bevacizumab as first-line maintenance therapy in patients with ovarian cancer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

INCYTE CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	001-12400	94-3136539
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)


1801 Augustine Cut-Off Wilmington, DE			19803
(Address of principal executive offices)			(Zip Code)

(302) 498-6700

(Registrant’s telephone number,

including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, $.001 par value per share	INCY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events.

Incyte Corporation (the “Company”) has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the Company’s selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer, which had been expected to begin in the fourth quarter of 2026.

The Company’s determination was based on the prioritization of its clinical development portfolio and was not based on any safety or efficacy findings from the INCB123667 clinical program. The Company does not expect this determination to affect its financial guidance or its previously disclosed long-term outlook.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 13, 2026
	INCYTE CORPORATION

	By:	/s/ Richard Hoffman
		Richard Hoffman
		Executive Vice President and General Counsel

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents